ELOXX PHARMACEUTICALS ($ELOX) posted quarterly earnings results for Q3 2026 on Monday, November 16th. The company reported earnings of -$0.49 per share, beating estimates of -$0.59 by $0.10. The company also reported revenue of $0, equaling estimates of $0 by $0.
Stock price change since market open this morning: -3.8%
You can see Quiver Quantitative's $ELOX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ELOXX PHARMACEUTICALS Hedge Fund Activity
We have seen 7 institutional investors add shares of ELOXX PHARMACEUTICALS stock to their portfolio, and 6 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ABERDEEN GROUP PLC added 400,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $5,552,000
- ECOR1 CAPITAL, LLC added 400,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $5,552,000
- SAMSARA BIOCAPITAL, LLC added 400,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $5,552,000
- MORGAN STANLEY added 201,086 shares (+13023.7%) to their portfolio in Q3 2026, for an estimated $3,078,626
- STONEPINE CAPITAL MANAGEMENT, LLC removed 65,183 shares (-14.6%) from their portfolio in Q3 2026, for an estimated $997,951
- GEODE CAPITAL MANAGEMENT, LLC added 19,946 shares (+inf%) to their portfolio in Q3 2026, for an estimated $305,373
- SEVEN GRAND MANAGERS, LLC removed 10,000 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $153,100
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
ELOXX PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $ELOX in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 10/28/2026
- Cantor Fitzgerald issued a "Overweight" rating on 10/15/2026
- Leerink Partners issued a "Outperform" rating on 09/18/2026
- LUCID CAPITAL MARKETS issued a "Buy" rating on 08/20/2026
- LifeSci Capital issued a "Outperform" rating on 07/22/2026
To track analyst ratings and price targets for ELOXX PHARMACEUTICALS, check out Quiver Quantitative's $ELOX forecast page.
ELOXX PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $ELOX recently. We have seen 4 analysts offer price targets for $ELOX in the last 6 months, with a median target of $39.0.
Here are some recent targets:
- Vamil Divan from Guggenheim set a target price of $40.0 on 10/28/2026
- Joseph Schwartz from Leerink Partners set a target price of $32.0 on 09/18/2026
- Dev Prasad from LUCID CAPITAL MARKETS set a target price of $38.0 on 08/20/2026
- Rami Katkhuda from LifeSci Capital set a target price of $40.0 on 07/22/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.